{
    "clinical_study": {
        "@rank": "293",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 10, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04334629"
        },
        "id_info": {
            "org_study_id": "282009",
            "nct_id": "NCT04334629"
        },
        "brief_title": "LIBA Trial in COVID-19",
        "acronym": "LIBA",
        "official_title": "Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial",
        "sponsors": {
            "lead_sponsor": {
                "agency": "King's College London",
                "agency_class": "Other"
            },
            "collaborator": {
                "agency": "Guy's & St Thomas NHS Foundation Trust",
                "agency_class": "Other"
            }
        },
        "source": "King's College London",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "The study aims to evaluate the reduction in severity and progression of lung injury with\n      three doses of lipid ibuprofen in patients with SARS-CoV-2 infections."
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 6, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "November 5, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "August 5, 2020"
        },
        "phase": "Phase 4",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "Double (Investigator, Outcomes Assessor)"
        },
        "primary_outcome": [
            {
                "measure": "Disease progression",
                "time_frame": "14 days",
                "description": "Worsening respiratory failure; defined using severity of hypoxaemia using [PaO2/FiO2 ratio OR SpO2/FiO2 ratio]"
            },
            {
                "measure": "Time to mechanical ventilation",
                "time_frame": "14 days",
                "description": "Time to mechanical ventilation (or need of)"
            }
        ],
        "secondary_outcome": [
            {
                "measure": "Overall survival",
                "time_frame": "28 days"
            },
            {
                "measure": "Reduction in proportion of patients who require ventilation",
                "time_frame": "28 days"
            },
            {
                "measure": "Reduction in length of Critical Care stay",
                "time_frame": "28 days"
            },
            {
                "measure": "Reduction in length of Hospital stay",
                "time_frame": "28 days"
            },
            {
                "measure": "Modulation of serum pro- and anti-inflammatory cytokines",
                "time_frame": "28 days"
            },
            {
                "measure": "Reduction in duration of ventilation",
                "time_frame": "28 days"
            },
            {
                "measure": "Increase in ventilator-free days",
                "time_frame": "28 days"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "230"
        },
        "condition": [
            "Coronavirus",
            "Respiratory Distress Syndrome",
            "SARS-CoV Infection"
        ],
        "arm_group": [
            {
                "arm_group_label": "Standard of care",
                "arm_group_type": "No Intervention"
            },
            {
                "arm_group_label": "Standard of care plus lipid ibuprofen",
                "arm_group_type": "Experimental"
            }
        ],
        "intervention": {
            "intervention_type": "Drug",
            "intervention_name": "Ibuprofen",
            "description": "Lipid ibuprofen 200 mg",
            "arm_group_label": "Standard of care plus lipid ibuprofen",
            "other_name": "Flarin"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female patients aged 18 years and above;\n\n          2. Hospitalised;\n\n          3. Confirmed or suspected SARS-CoV-2 infection;\n\n          4. National Early Warning Score (NEWS2) greater than or equal to 3 in a single parameter\n             or NEWS2 > 5 overall;\n\n          5. Acute hypoxemic respiratory failure: PaO2/FiO2 ratio less than or equal to 300 OR\n             SpO2/FiO2 ratio < 315 (Kigali Modification)\n\n          6. Provision of written informed consent by the patient OR by the patient's Legal\n             Representative OR professional consultee.\n\n        Exclusion Criteria:\n\n          1. Any of the following contraindications to ibuprofen:\n\n               -  A known hypersensitivity to ibuprofen or any other constituent of the medicinal\n                  product;\n\n               -  Patients who have previously shown hypersensitivity reactions (e.g. asthma,\n                  rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal\n                  anti-inflammatory drugs (NSAIDs);\n\n               -  Patients with a history of, or existing gastrointestinal ulceration/perforation\n                  or bleeding, including that associated with NSAIDs;\n\n               -  Patients with severe hepatic failure;\n\n               -  Patients with acute renal failure;\n\n               -  Patients with severe heart failure.\n\n          2. Participation in any other investigational drug products less than 30 days prior to\n             study enrolment;\n\n          3. Glasgow Coma Score < 12;\n\n          4. Pregnancy;\n\n          5. Any medical history that might, in the opinion of the attending clinician, put the\n             patient at significant risk if he/she were to participate in the trial;\n\n          6. DNAR order/limitation of care."
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Manu Shankar-Hari, MBBS",
            "role": "Principal Investigator",
            "affiliation": "Guys and St Thomas' NHS Foundation Trust"
        },
        "overall_contact": {
            "last_name": "Ndaba Mazibuko, MD",
            "phone": "07961949717",
            "email": "ndaba.mazibuko@nhs.net"
        },
        "overall_contact_backup": {
            "last_name": "Chloe Farrell, PhD",
            "phone": "07502447100",
            "email": "chloe.farrell@kcl.ac.uk"
        },
        "verification_date": "March 2020",
        "study_first_submitted": "April 2, 2020",
        "study_first_submitted_qc": "April 2, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 6, 2020"
        },
        "last_update_submitted": "April 2, 2020",
        "last_update_submitted_qc": "April 2, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 6, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "condition_browse": {
            "mesh_term": [
                "Coronavirus Infections",
                "Severe Acute Respiratory Syndrome",
                "Respiratory Distress Syndrome, Newborn",
                "Respiratory Distress Syndrome, Adult"
            ]
        },
        "intervention_browse": {
            "mesh_term": "Ibuprofen"
        },
        "patient_data": {
            "sharing_ipd": "Yes"
        }
    }
}